Abstract
Objective To measure patient and partner satisfaction with vardenafil treatment for erectile dysfunction (ED) using the TSS. Design and method A randomised, double-blind, placebo-controlled, parallel-group multicentre comparison of the efficacy and safety of vardenafil. Study participants (n=229 couples) were men with ED >6 months duration and their untreated partners aged > /=18 years without sexual dysfunction (Female Sexual Function Index score >26.55). Couples completed both the TSS and mSLQQ-QoL; men also completed the IIEF-EF. Analysis of covariance produced least squares (LS) mean domain scores. Results At LOCF, all TSS domain scores were significantly higher for vardenafil versus placebo for both patients (vardenafil vs placebo: ease with erection 61.18 vs. 35.01; erectile function satisfaction 53.17 vs. 10.48; pleasure from sexual activity 65.20 vs. 38.08; satisfaction with orgasm 60.81 vs. 27.82; confidence to complete sexual activity 59.70 vs. 26.01; satisfaction with medication 53.84 vs. 9.16; p Conclusions The TSS detected that treatment satisfaction with vardenafil was superior to placebo from both patient and partner perspectives. This study was supported financially by Bayer Healthcare.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
